menu
    • menu
    [{"orgOrder":0,"company":"Lion TCR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"LioCyx-M004","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lion TCR \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Not Applicable"},{"orgOrder":0,"company":"Lion TCR","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"TCR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lion TCR \/ Lion TCR","highestDevelopmentStatusID":"3","companyTruncated":"Lion TCR \/ Lion TCR"}]

    Find Clinical Drug Pipeline Developments & Deals by Lion TCR

    Menu

    Lion TCR

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lion TCR

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lion TCR

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte and Lion TCR Partner To Expand TCR-T Cell Pipeline Globally

                            Details : Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : TCR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lion TCR

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lion TCR

                            Singapore arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LioCyx-M004

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcin...

                            Details : This designation was granted based on the efficacy of LioCyx-M004, an autologous T-cells transfected with mRNA encoding HBsAg, as demonstrated by an improvement in the overall survival in patients with HBsAg-positive HCC relapsed or refractory to prior s...

                            Brand Name : LioCyx-M004

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 23, 2021

                            Lead Product(s) : LioCyx-M004

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth